Acorda to Present Data at the 3rd Pan American Parkinson’s Disease and Movement Disorders Congress

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it will present new data on INBRIJA (levodopa inhalation powder) and OFF Periods at the upcoming 3rd Pan American Parkinson’s Disease and Movement Disorders Congress (MDS-PAS) taking place February 14-16, 2020 in Miami, FL.

The data include four posters that will be presented on Saturday, February 15, 2020, from 1 – 2:30 PM ET:

• Poster #138 - CVT-301 utilization in clinical studies
• Poster #164 - Discussing OFF periods in Parkinson’s disease: expert panel feedback
• Poster #167 - Pharmacokinetics (PK) of inhaled levodopa co-administered with oral carbidopa in subjects with Parkinson’s disease under fed conditions
• Poster #LBA-9 - Improvement in UPDRS motor scores after CVT-301 treatment is associated with improved scores in the Parkinson's Disease Questionnaire activities of daily living

Acorda will also host a Corporate Therapeutics Symposium titled, “Rethinking the Approach to Managing OFF Periods” on Saturday, February 15, 2020 from 12:15 to 1:15 PM. The symposium will feature a panel discussion on the practical considerations for the recognition of OFF periods and the role of INBRIJA. Speakers will include Peter A. LeWitt, MD, Director of the Parkinson’s Disease and Movement Disorders Program at Henry Ford West Bloomfield Hospital, Fernando Pagan, MD, Director of the Movement Disorders Center at Georgetown University Hospital, and Mark Lew, MD, and Director of the Division for Movement Disorders at Keck/USC School of Medicine.

About Parkinson’s and OFF Periods

Parkinson’s is a progressive neurodegenerative disorder resulting from the gradual loss of certain neurons in the brain. These neurons are responsible for producing dopamine and that loss causes a range of symptoms including impaired movement, muscle stiffness and tremors. As Parkinson’s progresses, people are likely to experience OFF periods, which are characterized by the return of Parkinson’s symptoms, which can occur despite underlying baseline therapy. Approximately one million people in the U.S. and 1.2 million Europeans are diagnosed with Parkinson’s; it is estimated that approximately 40 percent of people with Parkinson’s in the U.S. experience OFF periods.